Cereno Scientific Sets Dec. 2 Investigator Meeting for Phase IIb CS1 Trial
Bitget2026/11/02 08:09- Cereno Scientific will host US investigators in Boston on December 2, 2026, to support its Phase IIb EPIMODE trial in pulmonary arterial hypertension.
- Up to 15 sites are expected to activate by year-end 2026; more than 50% of planned sites should activate by March 2027.
- Recruitment is targeted for completion during 2027, with topline results expected in the fourth quarter of 2028, subject to recruitment timelines.
- The placebo-controlled trial will evaluate CS1 added to standard care, enrolling approximately 126 patients across about 68 sites in 12 countries.
- Previously reported Phase IIa findings showed encouraging efficacy signals, including improved heart function and quality of life, with a favorable safety profile.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
